These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8111715)

  • 1. Histologic changes in prostate carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect). Distinction from poor tumor differentiation.
    Smith DM; Murphy WM
    Cancer; 1994 Mar; 73(5):1472-7. PubMed ID: 8111715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathology of androgen deprivation therapy in prostate carcinoma. A comparative study of 173 patients.
    Civantos F; Marcial MA; Banks ER; Ho CK; Speights VO; Drew PA; Murphy WM; Soloway MS
    Cancer; 1995 Apr; 75(7):1634-41. PubMed ID: 8826921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PSA flare in prostate cancer patients by administration of flutamide for 2 weeks before initiation of treatment with slow-releasing LH-RH agonist.
    Noguchi K; Uemura H; Harada M; Miura T; Moriyama M; Fukuoka H; Kitami K; Hosaka M
    Int J Clin Oncol; 2001 Feb; 6(1):29-33. PubMed ID: 11706524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic changes associated with androgen deprivation therapy for prostate cancer.
    Murphy WM; Soloway MS; Barrows GH
    Cancer; 1991 Aug; 68(4):821-8. PubMed ID: 1906775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early results of LH-RH agonist treatment with or without chlormadinone acetate for hormone therapy of naive localized or locally advanced prostate cancer: a prospective and randomized study. The Prostate Cancer Study Group.
    Akaza H; Homma Y; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Ohashi Y; Aso Y
    Jpn J Clin Oncol; 2000 Mar; 30(3):131-6. PubMed ID: 10798540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of flutamide in hormone-refractory metastatic prostate cancer.
    McLeod DG; Benson RC; Eisenberger MA; Crawford ED; Blumenstein BA; Spicer D; Spaulding JT
    Cancer; 1993 Dec; 72(12 Suppl):3870-3. PubMed ID: 8252506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effects of LH-RH agonist alone or with flutamide in the treatment of stage D2 prostate cancer].
    Ito T; Aizawa T; Yamamoto S; Ohkubo Y; Tsujino S; Miki M
    Hinyokika Kiyo; 1998 Jul; 44(7):477-80. PubMed ID: 9752601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not?
    Drew PA; Murphy WM; Kubilis PS; Areford M
    J Urol; 1997 Jun; 157(6):2201-5. PubMed ID: 9146615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squamous cell carcinoma of the prostate: a transformation from adenocarcinoma after the use of a luteinizing hormone-releasing hormone agonist and flutamide.
    Braslis KG; Davi RC; Nelson E; Civantos F; Soloway MS
    Urology; 1995 Feb; 45(2):329-31. PubMed ID: 7855985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands.
    Nishii M; Nomura M; Sekine Y; Koike H; Matsui H; Shibata Y; Ito K; Oyama T; Suzuki K
    J Androl; 2012; 33(6):1233-8. PubMed ID: 22492843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies in the treatment of metastatic prostate cancer.
    McLeod DG; Crawford ED; Blumenstein BA; Eisenberger MA; Dorr FA
    Cancer; 1992 Jul; 70(1 Suppl):324-8. PubMed ID: 1600494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical study on luteinising hormone-releasing hormone agonist depot formulation in the treatment of stage D prostatic cancer. The TAP-144-SR Study Group.
    Akaza H; Usami M; Koiso K; Kotake T; Aso Y; Niijima T
    Jpn J Clin Oncol; 1992 Jun; 22(3):177-84. PubMed ID: 1518166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
    Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
    Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of combined endocrine therapy on prostate and testis].
    Kong X; Zeng L; Xia T; Wang J; Mi P; Na Y; Xue Z; Pan B; Hao J; Gu F; Guo Y
    Zhonghua Wai Ke Za Zhi; 1999 Apr; 37(4):231-4. PubMed ID: 11829828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.